Brought to you by 
Roche buys GlycArt Biotechnology for CHF235mm
Jul 2005
Executive Summary
For about CHF235mm ($181.58mm) in cash, Roche has agreed to acquire all the outstanding capital stock of GlycArt Biotechnology AG, a private Swiss company developing enhanced antibodies, specifically with increased cytotoxicity, for cancer.
Deal Industry
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Cash
- Acquisition of Private Biotech
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Roche buys GlycArt Biotechnology for CHF235mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice